T-cell response to p 53 tumor-associated antigen in patients with colorectal carcinoma

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis

  2004cited by this paper
• Memory and flexibility of cytokine gene expression as separable properties of human TH1 and TH2 lymphocytes

  2003cited by this paper
• Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells.

  2002cited by this paper
• Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells.

  2002cited by this paper
• Immunotherapy of cancer through targeting of the p53 tumor antigen.

  2002cited by this paper
• CXCR5(+) T cells: follicular homing takes center stage in T-helper-cell responses.

  2002cited by this paper
• Live or let die: the cell's response to p53

  2002cited by this paper
• Long lasting p53‐specific T cell memory responses in the absence of anti‐p53 antibodies in patients with resected primary colorectal cancer

  2001cited by this paper
• Migration of dendritic cells into lymphatics-the Langerhans cell example: routes, regulation, and relevance.

  2001cited by this paper
• Regulatory functions of self-restricted MHC class II allopeptide-specific Th2 clones in vivo.

  2001cited by this paper
• p53 Website and analysis of p53 gene mutations in human cancer: Forging a link between epidemiology and carcinogenesis

  2000cited by this paper
• Clinical significance of defective dendritic cell differentiation in cancer.

  2000cited by this paper
• p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series.

  2000cited by this paper
• p53: A Potential Target Antigen for Immunotherapy of Cancer

  2000cited by this paper
• Strategies for immunotherapy of cancer.

  2000cited by this paper
• Prognostic significance of serum p53 antibodies in patients with limited‐stage small cell lung cancer

  2000cited by this paper
• Surfing the p53 network

  2000cited by this paper
• p53 Antibodies in the sera of patients with various types of cancer: a review.

  2000cited by this paper
• CD4+ T Cell Responses to Self- and Mutated p53 Determinants During Tumorigenesis in Mice1

  2000cited by this paper
• Cyclophosphamide enhances anti‐tumor effect of wild‐type p53‐specific CTL

  2000cited by this paper
• Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo

  1999cited by this paper
• Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factor–related Cytokine, TRAIL

  1999cited by this paper
• The Central Role of CD4+ T Cells in the Antitumor Immune Response

  1998cited by this paper
• Altered MHC class I antigens in tumors

  1997cited by this paper
• Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.

  1997cited by this paper
• Implications for immunosurveillance of altered HLA class I phenotypes in human tumours.

  1997cited by this paper
• Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes.

  1997cited by this paper
• p53 as a target for anti-cancer immunotherapy.

  1997cited by this paper
• Interleukin‐10 is a growth factor for human melanoma cells and down‐regulates HLA class‐I, HLA class‐II and ICAM‐1 molecules

  1997cited by this paper
• Effect of interleukin‐10 on dendritic cell maturation and function

  1997cited by this paper
• High frequency of altered HLA class I phenotypes in invasive breast carcinomas.

  1996cited by this paper
• Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic‐T‐cell responses: Evidence for immunoselection of antigen‐loss variants in vivo

  1996cited by this paper
• Therapy of murine tumors with p53 wild-type and mutant sequence peptide- based vaccines

  1996cited by this paper
• Primary proliferative T cell response to wild‐type p53 protein in patients with breast cancer

  1995cited by this paper
• Spontaneous apoptosis of dendritic cells is efficiently inhibited by TRAP (CD40‐ligand) and TNF‐α, but strongly enhanced by interleukin‐10

  1995cited by this paper
• In vivo gene therapy of human lung cancer using wild-type p53 delivered by retrovirus.

  1994cited by this paper
• Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity

  1994cited by this paper
• Linear antigenic sites defined by the B-cell response to human p53 are localized predominantly in the amino and carboxy-termini of the protein.

  1994cited by this paper
• Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation.

  1992cited by this paper
• p53 mutations in human cancers.

  1991cited by this paper
• A cell culture model for T lymphocyte clonal anergy.

  1990cited by this paper

• Relevance of Regulatory T Cells during Colorectal Cancer Development

  2020cites this paper